PUBLISHED: 8:38 PM 3 Jan 2018
UPDATED: 10:01 PM 3 Jan 2018

One-Time ‘Genetic’ Treatment Offers Blindness Cure, But Price Shows True Motivation

Steve Miller and others with Sparks feel that the therapy will be covered for most.

Steve Miller and others with Sparks feel that the therapy will be covered for most.

Usually, when a medical breakthrough happens, the joy is limitless, as the Conservative Daily Post showed to be the case in the science of bone regrowth technology. Sadly, when greed takes over, medicine and progress go by the wayside, something that the world is seeing today as a possible cure for blindness comes with a price tag that may as well resemble the national debt.

Bloomberg News reports that Spark Therapeutics is releasing a “transformative genetic treatment for a rare, inherited form of blindness” that they are saying will cost “$425,000 per eye, or $850,000 for both.” Though the company is said to be “tiny,” this is an injustice that makes the breakthrough as useless as garbage to most of the people who would benefit from it!

Luxturna was approved by the U.S. Food and Drug Administration in December and Sparks has said that they “will offer discounts based on whether or not the drug works initially and remains effective.” In other words, if it helps, expect the price to hamper access.

The FDA has championed such therapy’s but to what end if they can not be afforded?

There are between 1,000 and 2,000 people who suffer from the malady, a fact that means not as much as the bottom line, apparently.

We believe that this price reflects not only the breakthrough, life-altering value of one-time Luxturna, but it will enable us to continue to invest and build on the revolutionary science that supports not only Luxturna but the rest of our pipeline,” Chief Executive Officer Jeff Marrazzo said.

While it is a fact of life that Sparks deserves paid for the work that went into developing the drug (which is not cheap) and it is also true that they deserve to be paid well for what they have done, this reeks of profit. It would serve the company well, according to some, if no one supported them in the future over this pricing trick.

That does not seem to be happening. Already, stocks have gone up 1%.

There is talk of payment plans, the “spreading out of payments,” and cost changes if the effectiveness wains, but what help is that? It is cheaper if it does not work? Who does that help? Meanwhile, those that need help have to decide between eating and seeing…literally in some cases.

Will this drug be too expensive to help anyone?

At the end of the day, how many blind people have over $800,000 sitting around?

Many people were anticipating this would be more than a million dollars,” opined Steve Miller, the St. Louis-based company’s chief medical officer. “In the end, this is a revolutionary product, and I think in most plans this will be covered.”

Let us hope that he is correct. If not, this most wondrous of breakthroughs will be met by nothing but blinded, saddened stares.

Source: The Conservative Daily Post – Bloomberg News